Retension Pharmaceuticals Announces Completion of Series B Financing to Advance Phase 2b Trial for Uncontrolled and Resistant Hypertension and Issuance of a New U.S. Patent Covering its Lead Candidate, RTN-001 – Business Wire

Retension Pharmaceuticals Announces Completion of Series B Financing to Advance Phase 2b Trial for Uncontrolled and Resistant Hypertension and Issuance of a New U.S. Patent Covering its Lead Candidate, RTN-001  Business Wire